Retroperitoneal LiposarcomaTreatment Market – Drivers
The global RetroperitonealLiposarcoma Treatment Market is expected to exhibit a moderate growth rate,owing to low incidence of this disease across the globe. According to the WorldHealth Organization (WHO) 2016, liposarcoma is the most common type of sarcomas(cancer of soft tissue) and is classified as a rare disease, which accounts foraround 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore,rising incidence of genetic disorders is one of the major factors responsiblefor the global retroperitoneal liposarcoma treatment market growth. Accordingto a report published by the Genetics Education Center, University of KansasMedical Center, around 15% of all the cancers have an inherited susceptibilityand around 12% of the hospital admissions in the U.S. accounted for thetreatment of genetic causes in 2013. Various other factors contributing tomarket growth include changing lifestyle and growing awareness among populaceregarding availability of treatment for liposarcoma through initiatives undertakenby various organizations. For instance, Liposarcoma Genome Project initiativeby Massachusetts General Hospital Cancer Center conducted research tounderstand the differences between well-differentiated and de-differentiatedliposarcoma, to support the development of treatment for the rare disease.However, high costs associated with the treatment procedures and lowaccessibility of the treatment due to rareness of the disease are expected tobe factors hindering the market growth.
Retroperitoneal liposarcoma (RLS)is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum,lining of the abdominal space that covers the abdominal organs. Retroperitonealliposarcoma grow continuously and may not get diagnosed until they are verylarge thus, its prognosis is poor compared to the other subtypes ofretroperitoneal sarcomas.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1861
The reason for the development ofthese tumors are still unknown, however, genetic mutation is considered to beone of the factors leading to the generation of these tumors. Incidence of thisdisease is equal in men and women, with a slight predominance of men. Thistumor has no characteristic symptoms and are usually diagnosed during theadvanced stage.
Furthermore, the effectiveness ofradiotherapy or chemotherapy for the treatment of this tumor is not properlydefined, as they are massive in size and might involve adjacent visceral organsand critical structures. However, affected population who received adjuvantchemotherapy showed survival benefits and improvement, as compared to patientswho underwent surgery alone. In the case of surgeries, sometimes, preoperativeradiation is given to shrink the tumor. This allows smaller doses of radiationto a smaller field and make the surgery technically more feasible. The EuropeanOrganisation for Research and Treatment of Cancer (EORTC) is currentlyconducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiationtherapy) of pre-operative radiation therapy with short-course radiotherapy,followed by surgery to direct surgery alone. Thus, continuous researches thatare being conducted for the development of treatment for this disease isexpected to create lucrative opportunities in the retroperitoneal liposarcomatreatment market during the forecast period.
Retroperitoneal Liposarcoma TreatmentMarket - Regional Analysis
On the basis of region, theglobal retroperitoneal liposarcoma treatment market is segmented into NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa. NorthAmerica holds the maximum share for retroperitoneal liposarcoma treatment,owing to increasing research and development of novel therapies and potentialdrugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation ofAmerica (SFA) aids sarcoma patients by providing funding for research toprivate researchers and conducts education campaigns for patients sufferingfrom various types of sarcomas.
Browse Research Report:https://www.coherentmarketinsights.com/ongoing-insight/retroperitoneal-liposarcoma-treatment-market-1861
Furthermore, Asia pacific alsogenerates the significant value in retroperitoneal liposarcoma treatmentmarket, owing to the presence of significant population suffering from thedisease in this region. For instance, according to the Journal of Blood &Lymph 2013, in India around 35% of the patients suffering from sarcoma died dueto dedifferentiated liposarcoma.
Retroperitoneal liposarcomaTreatment Market – Competitor Landscape
Increasing regulatory approvalsby the U.S. FDA for various products manufactured by large companies isexpected to boost the overall growth of the retroperitoneal liposarcomatreatment market. For instance, in 2015, the U.S. FDA granted priority reviewfor the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured byJanssen Research & Development, LLC to treat patients with advanced softtissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in77 countries, within North America, Europe, South America, and Asia.Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for itsin-house developed anticancer agent Halaven (eribulin mesylate) for thetreatment of patients suffering from soft tissue sarcoma.
Market players operating in theglobal retroperitoneal liposarcoma treatment market include Eli Lilly andCompany, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., TevaPharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd.,Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, BedfordLaboratories, and Zydus Cadila.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1861
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
